| DAIC

November 27, 2023 — Esperion announced the presentation of results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023

Read more about Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

November 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced that the U.S.

Read more about Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

November 24, 2023 — During the American Heart Association Scientific Sessions 2023, held recently in Philadephia, PA, Milestone Pharmaceuticals Inc. announced positive Phase 2 data that show etripam

Read more about Positive Results from ReVeRA Phase 2 Study of Etripamil Nasal Spray in AFib-RVR Presented by Milestone Pharmaceuticals during AHA 2023

November 22, 2023 —

Read more about Renal HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms

November 22, 2023 — Medinbox, a leading global provider of video integrated collaboration sy

Read more about Medinbox Advances Company Mission to Improve Access to Medical Education and Remote Support Around the World with Debut of New Product Suites for Interventional Ecosystem at TCT

November 22, 2023 — The first clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction survivors with heart failure has enrolled its first patient.

Read more about Trial to Prevent Sudden Death After a Heart Attack Enrolls First Patient

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented additional Phase 3 data from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, at the American Heart Association (AHA

Read more about BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

November 21, 2023 — AccurKardia, an EC

Read more about AccurKardia Delivers its ECG Interpretation Software Within the Lucem Health Reveal Family of Clinical AI Solutions

November 21, 2023 — Heuron, a medical AI (artificial intelligence) imaging software solution company, under the leadership of CEO Dr. Donghoon Shin, is scheduled to take part

Read more about Heuron Showcasing Neuro AI Solutions and Presenting Abstract on AI Solutions for Stroke at RSNA23

November 20, 2023 — In the U.S., nearly 10,000 children and adolescents have developed a condition called multisystem inflammatory syndrome, or MIS-C, following

Read more about Investigators at Children’s Hospital Los Angeles Find Heart Complications in Many Children Treated for MIS-C